Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab